NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $4.18 +0.07 (+1.70%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$4.05 -0.13 (-3.06%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$3.93▼$4.2450-Day Range$3.71▼$5.4752-Week Range$0.93▼$5.81Volume805,409 shsAverage Volume1.15 million shsMarket Capitalization$345.13 millionP/E RatioN/ADividend YieldN/APrice Target$10.77Consensus RatingModerate Buy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 58% of companies evaluated by MarketBeat, and ranked 415th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOpus Genetics has a consensus price target of $10.77, representing about 157.6% upside from its current price of $4.18.Amount of Analyst CoverageOpus Genetics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.08) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 19.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.87% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 7.12.Change versus previous monthShort interest in Opus Genetics has recently increased by 46.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.63 News SentimentOpus Genetics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Opus Genetics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for IRD on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,596,606.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesJonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)June 27, 2026 | theglobeandmail.comOpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® IndexesJune 26, 2026 | globenewswire.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 2 at 1:00 AM | TradeSmith (Ad)Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 23, 2026 | americanbankingnews.comOppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)June 19, 2026 | theglobeandmail.comOpus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases TranscriptJune 17, 2026 | seekingalpha.comOpus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal DiseasesJune 16, 2026 | globenewswire.comGuggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price TargetJune 10, 2026 | finance.yahoo.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 at the start of the year. Since then, IRD shares have increased by 108.0% and is now trading at $4.18. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.59. The business earned $2.16 million during the quarter, compared to analysts' expectations of $2.93 million. Opus Genetics had a negative trailing twelve-month return on equity of 338.88% and a negative net margin of 892.36%. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today7/02/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 6 days, IRD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$10.77 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+157.6%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-892.36% Pretax Margin-892.36% Return on Equity-338.88% Return on Assets-191.21% Debt Debt-to-Equity RatioN/A Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual Sales$11.98 million Price / Sales28.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book19.00Miscellaneous Outstanding Shares82,566,000Free Float72,906,000Market Cap$345.13 million OptionableN/A Beta0.56 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:IRD) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredBillionaire Trader Warns: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
